ASX:NEU Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Neuren Pharmaceuticals Stock (ASX:NEU) 30 days 90 days 365 days Advanced Chart Get Neuren Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume57,935 shsAverage VolumeN/AMarket CapitalizationA$1.68 billionP/E Ratio14.31Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia. Read More Receive NEU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NEU Stock News HeadlinesNeuren Pharmaceuticals Quotes New Securities on ASXAugust 28, 2025 | tipranks.comNeuren Pharmaceuticals Sees Robust Profit Growth Amid Strategic Buy-BackAugust 26, 2025 | tipranks.comWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's latest plans for the dollar – and they're so bold that one central bank chair says we haven't seen anything like it in almost a century. Our Wall Street insider says it's the start of a once-in-a-lifetime investing opportunity, IF you act now.September 1 at 2:00 AM | Stansberry Research (Ad)Neuren Pharmaceuticals Initiates Phase 3 Trial for Phelan-McDermid SyndromeAugust 24, 2025 | tipranks.comNeuren Pharmaceuticals Issues New Securities to Strengthen Market PositionAugust 12, 2025 | msn.comCSL, Telix lead biotech selloff after Eli Lilly tanks on Wall StreetAugust 8, 2025 | msn.comWhy EOS, Eroad, Neuren, and Westgold shares are roaring higher todayAugust 8, 2025 | msn.comNeuren Pharmaceuticals Limited's (ASX:NEU) Stock Is Going Strong: Is the Market Following Fundamentals?August 5, 2025 | uk.finance.yahoo.comSee More Headlines NEU Stock Analysis - Frequently Asked Questions How were Neuren Pharmaceuticals' earnings last quarter? Neuren Pharmaceuticals Limited (ASX:NEU) posted its quarterly earnings results on Wednesday, February, 27th. The company reported $0.03 earnings per share (EPS) for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 55.28% and a net margin of 60.67%. What other stocks do shareholders of Neuren Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neuren Pharmaceuticals investors own include Oxford Lane Capital (OXLC), Pilbara Minerals (PLS), Sunrise Energy Metals (SRL), Westpac Banking (WBC), FBR (FBR), Embark Early Education (EVO) and Dream Industrial Real Estate Investment Trust (DREUF). Company Calendar Last Earnings2/27/2019Today9/01/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryChemicals Current SymbolASX:NEU CIKN/A Webwww.neurenpharma.com Phone61 3 9092 0480FaxN/AEmployees2,060Year FoundedN/AProfitability EPS (Trailing Twelve Months)A$0.93 Trailing P/E Ratio14.31 Forward P/E RatioN/A P/E GrowthN/ANet IncomeA$117.29 million Net Margins60.67% Pretax MarginN/A Return on Equity55.28% Return on Assets59.56% Debt Debt-to-Equity RatioN/A Current Ratio25.42 Quick Ratio31.54 Sales & Book Value Annual SalesA$193.34 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow12.46 Book ValueA$1.72 per share Price / BookN/AMiscellaneous Outstanding Shares130,070,000Free FloatN/AMarket CapA$1.68 billion OptionableNot Optionable Beta2.13 Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (ASX:NEU) was last updated on 9/1/2025 by MarketBeat.com Staff From Our PartnersRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredA Major Economic Change Is Happening NowLouis Navellier is one of Wall Street’s most respected money managers — overseeing more than $7 billion and ea...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…A new set of 7 AI stocks are DOMINATING the market. Here’s why one financial guru says they could be the mo...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuren Pharmaceuticals Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuren Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
